CD276 and ovarian cancer: Among the potential ADC targets in ovarian cancer, the immune checkpoint molecules B7-H3 (also known as CD276) and B7-H4 (also referred to as VTCN1, B7x, or B7S1) have emerged as particularly promising due to their overexpression in ovarian tumors and their role in immune evasion (26–28).